1 / 7

Mean fluorescence intensities of specific serum antibodies against various antigens

Serum antibodies against MAGE-A1. 10000. 1000. MFI. 100. 10. 1. BL. C1. C1. C2. C3. C4. BL. C1. C2. C3. BL. C1. BL. C1. C2. C3. BL. C1. BL. C1. C2. C3. BL. C1. BL. C1. BL. C1. BL. C1. C2. C3. BL. C1. C2. C3. C4. C5. C6. C7. C8. C9. BL. C1. BL. C1.

hadley-fowler
Download Presentation

Mean fluorescence intensities of specific serum antibodies against various antigens

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Serum antibodies against MAGE-A1 10000 1000 MFI 100 10 1 BL C1 C1 C2 C3 C4 BL C1 C2 C3 BL C1 BL C1 C2 C3 BL C1 BL C1 C2 C3 BL C1 BL C1 BL C1 BL C1 C2 C3 BL C1 C2 C3 C4 C5 C6 C7 C8 C9 BL C1 BL C1 BL C1 C2 C3 C4 C8 BL C1 C2 C4 BL C1 BL C1 C3 C8 BL C1 C2 C3 C4 BL C1 C2 C3 C4 C8 BL C2 C3 C4 C8 CL C1 C2 BL C1 C2 C3 C8 BL C1 C3 BL C1 C4 C8 BL C1 C2 C3 BL C1 C2 C8 BL C1 C2 C3 #01 #02 #03 #04 #05 #06 #08 #09 #10 #13 #16 #17 #18 #20 #24 #25 #27 #29 #30 #31 #32 #33 #34 #35 #36 #37 #38 #39 Patient number and vaccination cycle Legend for all graphs Median fluorescence intensity for specific antibody reactivity at the given treatment cycle BL C1 C2 C3 C4 C8 Cut-off for given antigen Treatment cycle; BL = baseline #01 Patient number MFI Median fluorescence intensity (logarithmic scale) Significant increase / decrease (> 2-fold; < 0.5-fold) between two measurements; both values above cut-off Significant increase / decrease (> 2-fold; < 0.5-fold) between two measurements; values cross cut-off (sero-conversion or sero-reversion) Mean fluorescence intensities of specific serum antibodies against various antigens Measurement of serum antibodies against various antigens before and during treatment. A bead-based assay was used for measuring specific serum antibodies. Beads of different color were coated with defined recombinant proteins and the binding of serum antibodies was measured and is given as median fluorescent intensity (MFI) of at least 100 beads per antigen. Significant increase or decrease of antibody titer was defined by at least two-fold change in MFI and is indicated by arrows. Green arrows delineate crossing of cut-off and thus show sero-conversions / sero-reversions. Most of the observed changes were titer increases (21 versus 5 decreases). Significant changes were observed mainly as fast titer change, i.e. between two consecutive blood draws. In four cases a gradually change in antibody titer was observed, where neighboring data points were not significant different, but distant ones were (marked by diagonal arrows). One example of a late and slow increase in antibody titer is seen in p16 antibody titer of patient #17. Most frequent antibody induction was found against p16. Specific high titer antibodies already before vaccination have been observed in 35 cases, 4 of which increased further (red arrows; MAGE-A1, A3, A9 and LAGE-1).

  2. Serum antibodies against MAGE-A3 MAGE-A3 cut-off 10000 1000 MFI 100 10 1 Serum antibodies against MAGE-A9 MAGE-A9 cut-off 10000 BL BL C1 C1 C1 C1 C2 C2 C3 C3 C4 C4 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 BL BL C1 C1 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 C2 C2 C3 C3 C4 C4 C5 C5 C6 C6 C7 C7 C8 C8 C9 C9 BL BL C1 C1 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 C4 C4 C8 C8 BL BL C1 C1 C2 C2 C4 C4 BL BL C1 C1 BL BL C1 C1 C3 C3 C8 C8 BL BL C1 C1 C2 C2 C3 C3 C4 C4 BL BL C1 C1 C2 C2 C3 C3 C4 C4 C8 C8 BL BL C2 C2 C3 C3 C4 C4 C8 C8 CL CL C1 C1 C2 C2 BL BL C1 C1 C2 C2 C3 C3 C8 C8 BL BL C1 C1 C3 C3 BL BL C1 C1 C4 C4 C8 C8 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 C2 C2 C8 C8 BL BL C1 C1 C2 C2 C3 C3 1000 #01 #01 #02 #02 #03 #03 #04 #04 #05 #05 #06 #06 #08 #08 #09 #09 #10 #10 #13 #13 #16 #16 #17 #17 #18 #18 #20 #20 #24 #24 #25 #25 #27 #27 #29 #29 #30 #30 #31 #31 #32 #32 #33 #33 #34 #34 #35 #35 #36 #36 #37 #37 #38 #38 #39 #39 Patient number and vaccination cycle Patient number and vaccination cycle MFI 100 10 1

  3. Serum antibodies against LAGE-1a LAGE-1a cut-off 10000 1000 MFI 100 10 1 BL BL C1 C1 C1 C1 C2 C2 C3 C3 C4 C4 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 BL BL C1 C1 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 C2 C2 C3 C3 C4 C4 C5 C5 C6 C6 C7 C7 C8 C8 C9 C9 BL BL C1 C1 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 C4 C4 C8 C8 BL BL C1 C1 C2 C2 C4 C4 BL BL C1 C1 BL BL C1 C1 C3 C3 C8 C8 BL BL C1 C1 C2 C2 C3 C3 C4 C4 BL BL C1 C1 C2 C2 C3 C3 C4 C4 C8 C8 BL BL C2 C2 C3 C3 C4 C4 C8 C8 CL CL C1 C1 C2 C2 BL BL C1 C1 C2 C2 C3 C3 C8 C8 BL BL C1 C1 C3 C3 BL BL C1 C1 C4 C4 C8 C8 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 C2 C2 C8 C8 BL BL C1 C1 C2 C2 C3 C3 #01 #01 #02 #02 #03 #03 #04 #04 #05 #05 #06 #06 #08 #08 #09 #09 #10 #10 #13 #13 #16 #16 #17 #17 #18 #18 #20 #20 #24 #24 #25 #25 #27 #27 #29 #29 #30 #30 #31 #31 #32 #32 #33 #33 #34 #34 #35 #35 #36 #36 #37 #37 #38 #38 #39 #39 Patient number and vaccination cycle Patient number and vaccination cycle Serum antibodies against CAMEL CAMEL cut-off 10000 1000 MFI 100 10 1

  4. Serum antibodies against GAGE-7b GAGE-7b cut-off 10000 1000 MFI 100 10 1 BL BL C1 C1 C1 C1 C2 C2 C3 C3 C4 C4 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 BL BL C1 C1 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 C2 C2 C3 C3 C4 C4 C5 C5 C6 C6 C7 C7 C8 C8 C9 C9 BL BL C1 C1 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 C4 C4 C8 C8 BL BL C1 C1 C2 C2 C4 C4 BL BL C1 C1 BL BL C1 C1 C3 C3 C8 C8 BL BL C1 C1 C2 C2 C3 C3 C4 C4 BL BL C1 C1 C2 C2 C3 C3 C4 C4 C8 C8 BL BL C2 C2 C3 C3 C4 C4 C8 C8 CL CL C1 C1 C2 C2 BL BL C1 C1 C2 C2 C3 C3 C8 C8 BL BL C1 C1 C3 C3 BL BL C1 C1 C4 C4 C8 C8 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 C2 C2 C8 C8 BL BL C1 C1 C2 C2 C3 C3 #01 #01 #02 #02 #03 #03 #04 #04 #05 #05 #06 #06 #08 #08 #09 #09 #10 #10 #13 #13 #16 #16 #17 #17 #18 #18 #20 #20 #24 #24 #25 #25 #27 #27 #29 #29 #30 #30 #31 #31 #32 #32 #33 #33 #34 #34 #35 #35 #36 #36 #37 #37 #38 #38 #39 #39 Patient number and vaccination cycle Patient number and vaccination cycle Serum antibodies against se70-2 se70-2 cut-off 10000 1000 MFI 100 10 1

  5. Serum antibodies against se57-1 se57-1 cut-off 10000 1000 MFI 100 10 1 BL BL C1 C1 C1 C1 C2 C2 C3 C3 C4 C4 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 BL BL C1 C1 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 C2 C2 C3 C3 C4 C4 C5 C5 C6 C6 C7 C7 C8 C8 C9 C9 BL BL C1 C1 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 C4 C4 C8 C8 BL BL C1 C1 C2 C2 C4 C4 BL BL C1 C1 BL BL C1 C1 C3 C3 C8 C8 BL BL C1 C1 C2 C2 C3 C3 C4 C4 BL BL C1 C1 C2 C2 C3 C3 C4 C4 C8 C8 BL BL C2 C2 C3 C3 C4 C4 C8 C8 CL CL C1 C1 C2 C2 BL BL C1 C1 C2 C2 C3 C3 C8 C8 BL BL C1 C1 C3 C3 BL BL C1 C1 C4 C4 C8 C8 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 C2 C2 C8 C8 BL BL C1 C1 C2 C2 C3 C3 #01 #01 #02 #02 #03 #03 #04 #04 #05 #05 #06 #06 #08 #08 #09 #09 #10 #10 #13 #13 #16 #16 #17 #17 #18 #18 #20 #20 #24 #24 #25 #25 #27 #27 #29 #29 #30 #30 #31 #31 #32 #32 #33 #33 #34 #34 #35 #35 #36 #36 #37 #37 #38 #38 #39 #39 Patient number and vaccination cycle Patient number and vaccination cycle Serum antibodies against GBP5ta GPB5ta cut-off 10000 1000 MFI 100 10 1

  6. Serum antibodies against cTAGE5a (N-terminus) cTAGE5a (N) cut-off 10000 1000 MFI 100 10 1 BL BL C1 C1 C1 C1 C2 C2 C3 C3 C4 C4 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 BL BL C1 C1 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 C2 C2 C3 C3 C4 C4 C5 C5 C6 C6 C7 C7 C8 C8 C9 C9 BL BL C1 C1 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 C4 C4 C8 C8 BL BL C1 C1 C2 C2 C4 C4 BL BL C1 C1 BL BL C1 C1 C3 C3 C8 C8 BL BL C1 C1 C2 C2 C3 C3 C4 C4 BL BL C1 C1 C2 C2 C3 C3 C4 C4 C8 C8 BL BL C2 C2 C3 C3 C4 C4 C8 C8 CL CL C1 C1 C2 C2 BL BL C1 C1 C2 C2 C3 C3 C8 C8 BL BL C1 C1 C3 C3 BL BL C1 C1 C4 C4 C8 C8 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 C2 C2 C8 C8 BL BL C1 C1 C2 C2 C3 C3 #01 #01 #02 #02 #03 #03 #04 #04 #05 #05 #06 #06 #08 #08 #09 #09 #10 #10 #13 #13 #16 #16 #17 #17 #18 #18 #20 #20 #24 #24 #25 #25 #27 #27 #29 #29 #30 #30 #31 #31 #32 #32 #33 #33 #34 #34 #35 #35 #36 #36 #37 #37 #38 #38 #39 #39 Patient number and vaccination cycle Patient number and vaccination cycle Serum antibodies against cTAGE5a (C-terminus) cTAGE5a (C) cut-off 10000 1000 MFI 100 10 1

  7. BL BL C1 C1 C1 C1 C2 C2 C3 C3 C4 C4 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 BL BL C1 C1 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 C2 C2 C3 C3 C4 C4 C5 C5 C6 C6 C7 C7 C8 C8 C9 C9 BL BL C1 C1 BL BL C1 C1 BL BL C1 C1 C2 C2 C3 C3 C4 C4 C8 C8 BL BL C1 C1 C2 C2 C4 C4 BL BL C1 C1 BL BL C1 C1 C3 C3 C8 C8 BL BL C1 C1 C2 C2 C3 C3 C4 C4 BL BL C1 C1 C2 C2 C3 C3 C4 C4 C8 C8 BL BL C2 C2 C3 C3 C4 C4 C8 C8 CL CL C1 C1 C2 C2 BL BL C1 C1 C2 C2 C3 C3 C8 C8 BL BL C1 C1 C3 C3 BL BL C1 C1 C4 C4 C8 C8 BL BL C1 C1 C2 C2 C3 C3 BL BL C1 C1 C2 C2 C8 C8 BL BL C1 C1 C2 C2 C3 C3 #01 #01 #02 #02 #03 #03 #04 #04 #05 #05 #06 #06 #08 #08 #09 #09 #10 #10 #13 #13 #16 #16 #17 #17 #18 #18 #20 #20 #24 #24 #25 #25 #27 #27 #29 #29 #30 #30 #31 #31 #32 #32 #33 #33 #34 #34 #35 #35 #36 #36 #37 #37 #38 #38 #39 #39 Patient number and vaccination cycle Patient number and vaccination cycle Serum antibodies against p53 p53 cut-off 10000 1000 MFI 100 10 1 Serum antibodies against p16 p16 cut-off 10000 1000 MFI 100 10 1

More Related